Multidrug resistance in cancer cells is often associated with an elevation in the concentration of glutathione ( GSH ) and the expression of -glutamylcysteine synthetase ( -GCS ), a rate -limiting enzyme for GSH. We constructed a hammerhead ribozyme against a -GCS heavy subunit ( -GCSh ) mRNA transcript and transfected it to human colonic cancer cells ( HCT8DDP ) resistant to cisplatin ( CDDP ). The effect of the ribozyme transfection on the drug resistance of cancer cells was studied. 
G lutathione ( -glutamylcysteinyl glycine, GSH ) participates in many biological processes especially cellular defense against oxidative stress induced by reactive oxygen species ( ROS ) and anticancer drugs. 1 -3 GSH is synthesized via two ATP -requiring steps catalyzed by -glutamylcysteine synthetase ( -GCS ), a rate -limiting enzyme for the synthesis of GSH, and GSH synthetase. The activity of -GCS is important to maintain the level of GSH. -GCS is composed of a heavy subunit ( -GCSh), which is catalytic, and a light subunit ( -GCSl ), which is regulatory. 4, 5 Quite recently, we have reported that the -GCS subunits are concomitantly expressed in response to cisplatin [ cisdiamminedichloroplatinum ( II ), CDDP ] in human cancer cells. 6 We also reported that CDDP is transported in the form of a CDDP-GSH adduct 7 and that GSH S-transferase ( GST ) detoxifies CDDP by forming the adduct with GSH and is important for the efflux of CDDP. 8 Overexpression of -GCS has been reported in many human malignant cells resistant to CDDP and doxorubicin. 6,9 -12 These results suggest that the high concentration of GSH is a factor for malignant cells in the acquisition of resistance to anticancer drugs in malignant cells.
There are other factors which account for the anticancer drug resistance of malignant cells: (a ) efflux system of drugs, and (b ) DNA repair system. ATP -binding cassette ( ABC ) transporters are a family of membrane proteins with similar characteristics such as two ATP -binding domains, intramembrane domains, and a function to efflux anticancer drugs. 13 Overexpression of ABC transporters has been reported in multidrug -resistant malignant cells. Recent investigations have explored the involvement of ABC transporters in CDDP resistance. 14 -19 In human cancer cells, the expression of several ABC transporters was found in CDDP -resistant cells together with up -regulation of GSH and GST. 15, 16, 18 Then, CDDP resistance may be obtained through multiple pathways. Notably, a role for MRP1 and cMOAT in the efflux of CDDP was indicated.
The close relation between the expression of cMOAT and CDDP resistance has been analyzed in patients with colorectal cancer, 17 and a similar finding has been reported by Materna et al 19 using anti -cMOAT hammerhead ribozymes.
Concerning the expression of -GCS, Manna et al 20 have reported that overexpression of -GCSh suppresses tumor necrosis factor-induced apoptosis and the DNAbinding activity of nuclear factor-kappa B (NF -B ) and activator protein -1 (AP -1), strongly suggesting a role of -GCS in regulating cell proliferation and death. Gomi et al 21 have reported that MRP1 and -GCS are concomitantly induced by an antitumor nitrosourea. Similarly, Yamane et al 22 have reported that oxidative stress upregulates the expression of these two genes. These results suggest that there are co -regulatory mechanisms for the expression MRP1 and -GCS, and that transfection of cancer cells with a hammerhead ribozyme against -GCSh to reduce the expression of -GCSh suppresses the expression of MRP1.
In the present study, we employed hammerhead ribozyme against -GCSh to suppress the -GCSh gene expression especially, and examined the effect of a hammerhead ribozyme against -GCSh on the CDDP resistance of human colonic cancer cells (HCT8DDP ). Hammerhead ribozymes are derived from satellite RNA of tobacco ring spot virus, and are newly developed trans -acting RNA enzymes that modulate specific gene expression. 23, 24 The hammerhead ribozymes possess a catalytic core that cleaves the target RNA and flanking regions that direct the ribozyme core to a specific target site. 25, 26 A previous report has shown that hammerhead ribozymes against -GCS caused downregulation of the intracellular GSH concentration in mouse islet cells. 27 Here we show that the decrease in the levels of GSH induced by anti --GCSh ribozyme caused a concomitant decrease in the expression of MRP1, which then decreased the transport activity of CDDP and increased the sensitivity of cancer cells to CDDP.
MATERIALS AND METHODS

Cell culture
We used human colonic cancer cells resistant to CDDP ( HCT8DDP ) and human ovarian cancer cells (A2780 ) in this study. Cancer cells were maintained in RPMI 1640 ( Gibco BRL, Gaithersburg, MD ) supplemented with 10% fetal calf serum at 378C in 5% CO 2 under 100% humidity. HCT8DDP cells were treated with 100 M CDDP for 2 hours a week.
Estimation of GSH
The concentration of intracellular GSH was estimated enzymatically as described by Beutler. 28 Transport of CDDP CDDP binds to two GSH by the catalytic reaction of GST. 8 The transport of CDDP -GSH adduct was studied essentially as described. 2 Briefly, cells incubated with 45 Ci of [ 3 H ]Lglycine ( 25 Ci /nmol ) for 2 hours at 378C were washed with the incubation medium. They were then incubated in 5 mL of a medium containing 100 M CDDP for 1 hour and washed for three times with this medium to remove the extracellular CDDP and estimate the amount of CDDP -GSH intracellularly formed. Then, the other cells were further incubated with 5 mL of this medium for 1 hour. After centrifugation, the supernatant was extracted with trichloroacetic acid, and analyzed on an HPLC column ( TSK gel NH 2 -60; Tosoh, Tokyo, Japan ). The radioactivity and the concentration of platinum of the CDDP-GSH fraction were estimated using a scintillation counter and an atomic absorption spectrophotometer ( Seiko Instrument, Tokyo, Japan ).
Plasmid construction and transfection
The anti --GCSh ribozyme was cloned into the pHplasmid using two synthetic, single-stranded oligodeoxynucleotides: 5 0 -TCGACTGTATTGCTGATGAGTCCG TGA-GGACGAAACTCGGAA -3 0 and 5 0 -AGCTTTCCGAGTT-TCGTCCTCA CGGACTCATCAGCAATACAG -3 027 with flanking SalI and HindIII restriction sites. Subconfluent HCT8DDP cells were transfected with the pH -plasmid using Lipofectin Reagent ( Gibco BRL ). Stably transfected cells were selected for integration of plasmid in growth media containing 500 g /mL of G418 sulfate for 4 weeks. Selected G418 -resistant colonies were grown and screened for expression of the ribozyme by reverse transcription polymerase chain reaction ( RT-PCR ) assay. 27 The ribozyme -transfected cells, in which GSH concentration decreased approximately by 50%, were further selected and used in the present experiments. Disabled hammerhead ribozyme was synthesized by PCR with the following primers: 5 0 -TCCGAGTTTCGTCCTCACGGACTCAT-3 0 and 5 0 -TAATACGACTCACTATAGTGTATTGCTAATGA-GTCCGTGA -3 0 . The disabled ribozyme contained a single base exchange ( G to A ) in the catalytic core compared with the original ribozyme. 27 Northern blot analysis A 764-base pair (bp ) DNA fragment ( 865-1628 bp) of full -length -GCSh cDNA was obtained as described. 6 A 292 -bp DNA fragment ( 4109 -4400 bp ) containing the complete coding sequence of the human MRP1 was generated by RT-PCR from the total RNA of HCT8DDP cells as a template for the MRP1 cDNA. 29 The forward (5 0 -GGACCTGGACTTCGTTCTCA -3 0 ) and reverse ( 5 0 -CGTCCAGATTCCTTCATCCG -3 0 ) primers were designed. A 559 -bp DNA fragment (2628 -3186 bp) containing the complete coding sequence of the human cMOAT was generated by RT-PCR from the total RNA of HCT8DDP cells as a template for the cMOAT cDNA. 30 The forward ( 5 0 -GAAGACGATGACTATGGGCTGA -3 0 ) and reverse ( 5 0 -ACGAAACCAAAGGCACTCCAGA -3 0 ) primers were designed. A 308 -bp DNA fragment ( 14-321 bp ) containing the complete coding sequence of the human MDR1 was generated by RT-PCR from the total RNA of HCT8DDP cells as a template for the MDR1 cDNA. reverse ( 5 0 -CAGATTCATGAAGAACCCTG -3 0 ) primers were designed. A 1183 -bp DNA fragment ( 1 -1183 bp ) containing the complete coding sequence of the human p53 was generated by RT-PCR from the total RNA of HCT8DDP cells as a template for the p53 cDNA. 32 The forward (5 0 -ATGGAGGAGCCGCAGTCAGAT-3 0 ) and reverse (5 0 -TCAGTCTGAGTCAGGCCCTTC -3 0 ) primers were designed.
The probes used were as follows: ( a) a -GCSh probe ( 764 bp), ( b) a MRP1 probe (292 bp ), (c ) a cMOAT probe ( 559 bp ), (d ) a MDR1 probe (308 bp ), and ( e) a p53 probe (1183 bp) prepared as described above. These probes were radiolabeled with [ 32 P ]dCTP using Random Primer DNA Labeling kit (Takara, Tokyo, Japan ). Isolation of cytoplasmic RNA and Northern blotting were essentially as described by Sambrook et al. 33 Cytoplasmic RNA isolated from cells were subjected to electrophoresis in 1% agarose gel containing 0.6 M formaldehyde, subsequently transferred to nylon membranes, and then hybridized with 32 P -labeled probes. Autoradiographed membranes were analyzed using a Fujix Bio -Analyzer BAS -5000 (Fuji Photo Film, Tokyo, Japan ). After stripping, the membranes were rehybridized with 32 P-labeled glyceraldehyde 3 -phosphate dehydrogenase (GAPDH ) probe, and the intensity of the bands was estimated. The relative radioactivity was expressed as a ratio of photostimulated luminescence corrected by the intensity of GAPDH.
Preparation of nuclear extracts
Nuclear extracts were prepared as described by Abmayr and Warkman. 34 Briefly, the cells were suspended in hypotonic buffer, 10 mM HEPES, pH 7.9, containing 1.5 mM MgCl 2 , 10 mM KCl, 0.2 mM PMSF, and 0.5 mM DTT. The swollen cells were homogenized and the nuclei pelleted. Gentle dropwise addition of a high -salt buffer, 20 mM HEPES, pH 7.9, containing 25% glycerol, 1.5 mM MgCl 2 , 1.2 M KCl, 0.2 mM EDTA, 0.2 mM PMSF, and 0.5 mM DTT released the soluble proteins from the nuclei. The soluble nuclear extract was prepared by removing precipitable proteins by centrifugation.
Electrophoretic mobility shift assay
The electrophoretic mobility shift assay for AP -1 and SP1 was performed as described by Sen and Baltimore 35 with a slight modification. Briefly, nuclear extracts were incubated with an AP -1 or SP1 -specific 32 P oligonucleotide. The binding reaction proceeded in 25 L of reaction mixture containing 10 g of extract, 5 L of a binding buffer (10 mM Tris, pH 7.5, 50 mM NaCl, 1 mM EDTA, 1 mM DTT, 4% glycerol ), 0.08 mg /mL sonicated salmon sperm DNA, and labeled oligonucleotide (3000 -6000 cpm ). After a 20 -minute binding reaction at room temperature, samples were loaded on a 6% nondenaturing polyacrylamide gel and subjected to electrophoresis in 25 mM Tris, 22.5 mM borate, and 0.25 mM EDTA, pH 8.0. For the specificity control, a 100 -fold excess of unlabeled probe was applied. The sequence of the binding site for the SP1 probe was 5 0 -CGAGGTGAGCAGGCGCCGGGGCGGGCGGGGTGG-GGCGGGGCC -3 0 and 3 0 -CTCGTCCGCGGCCCCGCC-CGCCCCACCCCGCCCCGGAGGCG -5 0 , specific for the sequences of the promoter of MRP1. 36 The DNA -binding activity of the extracts was quantified by estimating the amount of the 32 P-labeled SP1 -DNA complex excised from the dried gels. To deplete the nuclear p53 protein, p53 protein was immunoprecipitated from nuclear protein extracts using mouse anti -human p53 monoclonal antibody ( Oncogene Research Product, Cambridge, MA ). One hour after the incubation of the nuclear extract with the antibody, the incubation mixture was mixed with a Protein A Sepharose resin (Amersham Pharmacia Biotech, Piscataway, IIDA, KIJIMA, URATA, ET AL: EFFECT OF ANTI --GCS RIBOZYME ON THE MULTIDRUG RESISTANCE NJ ). After centrifugation, the supernatant was employed as p53 free nuclear extracts.
DNA sequence of p53
The DNA sequence of p53 was estimated using a RT-PCR product of p53 from HCT8DDP cells by a DNA sequence analyzer ( ALF DNA sequencer; Amersham Pharmacia Biotech ).
Western blot analysis
For MRP1, protein was determined according to the published procedure. 37 Briefly, cells were lysed in lysing buffer (10 mM Tris -HCl, pH 7.4, 10 mM KCl, 1.5 mM MgCl 2 , 2 mM phenylmethylsulfonyl fluoride, 2 g aprotinin / mL, 200 g EDTA / mL, 200 g benzamidine/ mL, and 1 g pepstatin /mL ) by sonication. The lysate was clarified by centrifugation at 10,000Âg for 5 minutes. The supernatant was mixed with an equal volume of 500 mM sucrose, and centrifuged at 100,000Âg for 30 minutes. The membrane -enriched fraction was resuspended in the lysing buffer containing 250 mM sucrose. The lysate ( 10 g ) was separated by 7.5% SDS -PAGE in a gel, transferred to a nitrocellulose membrane, and blotted with anti-MRP1 monoclonal antibody (QCR 1; Chemicon International, Temecula, CA ) and an anti -mouse IgG (HRP -linked second antibody ) (Amersham Pharmacia Biotech ). Blots were developed by enhanced chemiluminescence using ECL kit (Amersham Pharmacia Biotech ). For p53 and SP1, proteins were determined according to the published procedure. 32 Briefly, cells scraped were washed with phosphate -buffered saline containing 1 mM phenylmethylsulfonyl fluoride and centrifuged at 1000Âg for 4 minutes. Protease inhibitors containing 1 mM phenylmethylsulfonyl fluoride and 1 mM benzamidine were added before use. The lysate ( 10 g ) was separated by 10% SDS -PAGE in a gel using anti -p53 monoclonal antibody ( Oncogene Research Products) or anti -SP1 polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA ). The bound antibodies were developed using ECL kit. The protein concentration was determined according to Redinbaugh and Turley 38 with bovine serum albumin as the standard. Levels of p53 and SP1 in the nuclei were estimated by Western blots using the nuclear extract for an electrophoretic mobility gel shift assay.
Cytotoxicity assay
The sensitivity of the cells to CDDP was assayed by tetrazorium salt assay ( MTT ) as described. 7, 39 Cells ( 1500 - 5000 ) were place in 100 L of medium per well in 96-well plates. Twenty -four hours after the treatment with various concentrations of CDDP, the cells were incubated for 4 hours at 378C with 3 -( 4,5-dimethylthiazol -2 -yl ) -2,5 -diphenyltetrazolium bromide (652 g /mL ). The cells were lysed with 100 L of 20% SDS /50% N,N -dimethyl -formamide ( pH 4.7 ) in each well. After an overnight incubation at 378C, the absorbance at 570 nm was measured. Wells without cells served as blanks.
Statistical analysis
Data were presented as the mean ± SD. Differences were examined using the Student's t test. A P value <.05 was considered significant. Figure 1 shows the characteristics of HCT8DDP cells transfected with hammerhead ribozyme against anti --GCSh. The transfection resulted in a significant decrease in the expression of -GCSh mRNA by approximately 50% in cloned cells (ribozyme -1) and 35% in other cloned cells ( ribozyme -2 ) (P <.05 versus the cells transfected with disabled ribozyme, respectively ) ( Fig 1, A and B Fig 1C ) . The activities of GSH -related enzymes, such as GSH peroxidase and GSH reductase, in the ribozyme -transfected cells did not change compared to controls ( data not shown ).
RESULTS
Suppression of the GSH levels by the ribozyme
Sensitivity to CDDP
The effect of different concentrations of CDDP on the cell survival was studied. The cells were treated with various concentrations of CDDP for 24 hours and the cell viability was estimated by a cytotoxicity assay (MTT assay ). The data are the mean ± SD of three independent analyses. *P < .05 versus + disabled ribozyme. IIDA, KIJIMA, URATA, ET AL: EFFECT OF ANTI --GCS RIBOZYME ON THE MULTIDRUG RESISTANCE 100 M CDDP and did not show any apparent change up to 500 M CDDP. In contrast, the cell viability in HCT8DDP cells transfected with anti --GCSh ribozyme decreased to 35% by 100 M CDDP in ribozyme -1 and to 45% by 100 M CDDP in ribozyme -2, and these cells showed increasing cytotoxicity up to 300 M CDDP, in a dose -dependent manner.
Transport activity of CDDP
CDDP is transported outside the cells as a form of CDDP -GSH adduct. The effect of the transfection of anti --GCSh ribozyme on the transport activity of CDDP was studied. The levels of CDDP -GSH adduct intracellularly formed were 2.9± 0.1 pmol /10 6 cells in HCT8DDP cells and 2.8 ± 0.1 pmol /10 6 cells in the cells transfected with disabled ribozyme, whereas they decreased in ribozyme -1 (1.5 ± 0.1 pmol /10 6 cells ) and in ribozyme -2 ( 2.0± 0.4 pmol /10 6 cells) (P <.05 versus the cells transfected with disabled ribozyme, respectively ). Figure 3 shows the transport activity of CDDP -GSH adduct. The activity was 3.1 ± 0.6 pmol / 10 6 cells/h in HCT8DDP cells, and 3.0 ± 0.6 pmol / 10 6 cells /h in the cells transfected with disabled ribozyme. It decreased by 44% in ribozyme -1 (1.3 ± 0.3 pmol/10 6 cells/h ) and 65% in ribozyme -2 (2.0 ± 0.4 pmol / 10 6 cells/h ) ( P <.05 versus the cells transfected with disabled ribozyme, respectively ). Figure 4 shows the results of Northern blot analysis for ABC transporters. Transfection of anti--GCSh ribozyme caused a decrease in the expression of MDR1, MRP1, and cMOAT mRNA in ribozyme -1 by 40%, 35%, and 44% of that in HCT8DDP cells transfected with disabled ribozyme (P < .05, respectively ). Similarly, the transfection caused a decrease in the expression of MDR1, MRP1, and cMOAT mRNA in ribozyme -2 by 65%, 55%, and 68% of that in the cells transfected with disabled ribozyme ( P <.05, respectively ). Figure 5 shows the results of Western blot analysis for MRP1. A concomitant decrease in the immunological levels of MRP1 was observed in the anti --GCSh ribozymetransfected cells.
Expression of ABC transporters
Expression of p53
It has been reported that transfection of wild p53 to cancer cells causes an inhibition of the expression of MRP1 mediated by SP1. 33 The effect of anti --GCSh ribozyme on the expression of p53 was estimated. Figure 6 shows the expression of p53 mRNA. The expression of p53 mRNA was elevated in HCT8DDP cells transfected with anti --GCSh ribozyme by approximately 1.6 -fold in ribozyme -1 and by 1.5-fold in ribozyme -2 compared to that in the cells transfected with the disabled ribozyme (P < .05, respectively ). Figure 7 shows the levels of p53 protein.
Concomitant increase in the levels of p53 protein was observed in the cells with anti--GCSh ribozyme. Figure  8 , A and B shows the results of treating the HCT8DDP cells with 0.1 mM buthionine sulfoximine ( BSO ), a specific inhibitor of -GCS, or 10 mM GSH methylester (Sigma Chemical, St. Louis, MO ) for 24 hours. Treatment of the cells with BSO resulted in a significant decrease in the GSH concentration to 32% and a significant increase in the p53 mRNA levels to 158%. Treatment of the cells with GSH methylester resulted in an increase in the GSH concentration to 135% and a decrease in the p53 mRNA levels to 73% (P < .05, respectively ). In order to know if p53 in HCT8DDP possesses mutation( s ), the sequence of p53 corresponding to base pairs ( 1-1183 ) of the p53 gene was studied by RT-PCR. It was found that C at the 80th nucleotide changed to T, corresponding to the change from proline to leucine at the 27th amino acid by three independent analyses. This mutation is located outside of the domain important for the DNA -binding and the protein -protein interaction. 32 The data suggest that a decrease in the concentration of GSH purely causes an increase in the expression of p53 in HCT8DDP cells. To confirm the regulation of p53 expression by GSH, the effect of GSH on the p53 expression was examined using human ovarian cancer cells (A2780 cells ) possessing the wild -type p53. 40 Figure 8 , C and D shows the results of Northern blot analysis of p53 in A2780 cells previously treated with BSO or GSH methylester. A similar effect of the change in the GSH concentration in A2780 cells was observed on the expression of wild -type p53 as on that of a mutant p53 in HCT8DDP cells. Figure 9A shows the results of electrophoretic mobility shift assay for SP1. Transfection of anti --GCSh ribozyme into HCT8DDP cells reduced the SP1 -DNA binding activity ( lanes 3 and 4 ) . Depletion of the nuclear p53 protein resulted in a restoration of the SP1 -DNA binding activity in the ribozyme -transfected cells ( lane 5 versus lane 3; lane 6 versus lane 4 ). When A2780 cells, in which p53 is the wild type, were treated with 0.1 mM BSO for 24 hours, a reduction in the GSH levels by 59% concomitant with a decrease in the SP1 -DNA binding activity occurred (lanes 7 and 8 ), whereas treatment of A2780 cells with GSH methylester for 24 hours caused an increase in the GSH levels by 140% concomitant with an increase in the SP1 -DNA binding activity (lane 9 ). Depletion of the nuclear wild -type p53 protein in A2780 cells resulted in a similar restoration of the SP1 -DNA binding activity as observed in HCT8DDP cells (lane 10). GSH seemed to play a role in regulating SP1 activity. Figure 9B shows the results of Figure 8 . Effect of GSH levels on the expression of p53. Effect of GSH levels on the expression of p53 was studied using HCT8DDP ( A ) and A2780 cells ( C ). These cells were treated with BSO or GSH methylester for 24 hours and the effect of these treatments on the expression of p53 mRNA was examined by Northern blot analysis. The relative amounts of radioactivity are expressed as a percentage of PSL ( B ) and ( D ). Each lane corresponds to the lane in ( A ) and ( C ), respectively. The data are the mean ± SD of three independent analyses. *P < .05 versus control.
Electrophoretic mobility shift assay
Cancer Gene Therapy, Vol 8, No 10, 2001 IIDA, KIJIMA, URATA, ET AL: EFFECT OF ANTI --GCS RIBOZYME ON THE MULTIDRUG RESISTANCE Western blot analysis for SP1 and p53 proteins in the nucleus. The nuclear SP1 proteins ( p95 and p106) were increased in HCT8DDP cells transfected with anti --GCS ribozyme ( upper panel, lane 5) compared to HCT8DDP cells transfected with the disabled ribozyme (lane 3 ). Next, we studied the effect of treatment of cell nuclear extracts with anti -p53 antibody on the amount of nuclear p53 and SP1. Almost all of the nuclear p53 proteins were depleted by the treatment (lower panel, lanes 2, 4 and 6). The removal of p53 protein had no apparent effect on the amount of nuclear SP1 proteins compared to each control ( 1, 3, and 5) . No SP1 proteins were observed in the Protein A Sepharose resin. 7 -9 This suggests that the mutant p53 protein in HCT8DDP cells retains the activity for transcriptional suppression of SP1.
DISCUSSION
In the present study, to elucidate the effect of the continuous suppression of GSH synthesis on the multidrug resistance of cancer cells, we employed anti --GCSh ribozyme, and the transfection of it into cancer cells effectively decreased the levels of GSH (Fig 1 ) , and the transport of CDDP -GSH adduct was inhibited in HCT8DDP cells transfected with anti --GCSh ribozyme (Fig 3 ) . This decrease in the GSH levels and the transport of CDDP-GSH related to the increase in the sensitivity of HCT8DDP cells to CDDP ( Fig  2 ) . Quite recently, Tipnis et al 42 reported that overexpression of -GCSh in HeLa cells causes resistance to CDDP. Together with other reports on the overexpression of -GCS in CDDP-resistant cancer cells, 6,9 -12 increase in the GSH synthesis closely relates to drug resistance of cancer cells to CDDP. Our data, that suppression of -GCSh expression caused an increase in the sensitivity to CDDP, are in good agreement with these reports.
Several steps are involved in an increase in the efflux of CDDP in cancer cells: ( a) expression of -GCS to increase the GSH synthesis; (b ) expression of GST to increase the adduct formation of CDDP with GSH; and ( c) expression of ABC transporters to efflux the CDDP -GSH adducts. We have shown that the expression of both -GCSh and -GCSl mRNA was concomitantly increased in cells resistant to CDDP and that the increase in the GSH levels was accompanied by the induction of -GCSh and -GCSl proteins. 6 The formation of CDDP -GSH adducts is catalyzed by GST, 8 so high levels of both GSH and GST are important for the formation. The CDDP -GSH adduct is actively transported outside the cells dependent on the intracellular concentration of GSH 7 and the activity of GST. 8 It has been reported that an increase in the expression of GST, together with a high concentration of GSH, was involved in resistance to CDDP. 43, 44 The activity of GST in HCT8DDP cells was higher than that in HCT8 cells, which are relatively sensitive to CDDP. 7 But the expression of GST mRNA did not change in HCT8DDP cells transfected with anti --GCSh ribozyme ( data not shown ). The formation of CDDP -GSH in HCT8DDP cells transfected with anti --GCSh ribozyme was approximately 50 -70% of that in the control cells. These results suggest that the decrease in CDDP-GSH adduct is due to a decrease in GSH levels.
The CDDP -GSH adduct is transported through ABC transporters, especially through cMOAT, 17, 19 and MRP1 also participates in this adduct transport and is important in CDDP resistance. 45 Ishikawa et al 46 have reported that the expression of MRP1 is associated with overexpression of -GCS in CDDP -resistant cells. Kuo et al 47 demonstrated that -GCS and MRP1 are frequently co-expressed, suggesting their functional correlation. These results strongly support the idea that MRP1 and -GCS gene expression is involved in the acquisition of drug resistance in cancer cells. Although a correlation between the expression of -GCS and MRP1 in the resistance of cells to CDDP was indicated, the molecular basis of the effect of -GCS and GSH on the expression of ABC transporter genes has not been clarified.
Interestingly, the transfection of anti --GCSh ribozyme caused a reduction in the number of ABC transporters, such as MDR1, MRP1, and cMOAT, as observed on Northern ( Fig 4) and Western ( Fig 5) blots. Cancer cells resistant to CDDP express various ABC transporters, 16, 18 though it is not certain if all of these genes are involved in CDDP resistance.
Transcriptional regulation of ABC transporter genes has been reported. Involvement of SP1 in the regulation of the expression has been reported for MDR1 48 and MRP1. 49 There are other transcriptional factors for the expression of ABC transporter genes, such as YB -1 for MDR1 50, 51 or AP -1 for MDR1. 52 In the electrophoretic gel mobility shift assay ( Fig 9 ) , down -regulation of the SP1 -DNA binding activity was observed in the anti --GCSh ribozyme -transfected cells. This suggests that SP1 activity is involved in the regulation of the gene expression of ABC transporters by GSH.
Quite recently, Wang and Beck 32 have reported that MRP1 gene expression mediated by SP1 is down -regulated by p53, suggesting that nuclear p53 binds to SP1 transcriptional proteins and suppresses the transcriptional activity of MRP1. Sullivan et al 53 have reported a mechanistic linkage between the expression of MRP1 and mutant p53. MRP1 was induced by transfecting cancer cells with p53 inactivated by papilloma virus or with a dominant negative mutant of p53. Similarly, Ishikawa et al 54 reported that the expression of MRP1 and -GCS and mutation of p53 are associated. The ability of p53 to regulate the expression of MRP1 seems to be dependent on the degree of mutation in p53. It has been reported that both wild -type and mutant p53 form a heterocomplex with SP1 and bind to the SP1 recognition site in Jurkat cells. 55 In the present study, we found that p53 protein is up -regulated by the ribozyme transfection (Fig 7 ) . p53 protein is a negative regulator of cell proliferation and induces genes that are involved in growth arrest, DNA repair, and apoptosis. 56 The human p53 protein consists of 393 amino acids and is organized into three functional domains: a transcriptional domain in the N -terminal region, a specific DNA -binding domain in the central region, and a transcriptional repression domain in the C -terminal region. 57 Approximately 50% of cancers contains mutations in the p53 gene. Mostly, they are single missense point mutations located within the central region (amino acid residues 100-300 of the p53 protein ) and these mutant p53 proteins lose the tumor-suppresser function. 58 In the present study, a mutation of p53 in HCT8DDP cells was found in a transcriptional domain. SP1 -DNA binding activity was suppressed by the wild -type p53 in A2780 cells as it was by a mutant p53 in HCT8DDP cells, suggesting that the inhibitory activity of SP1 transcription seems to be same in these cancer cells with wild and mutant type p53 (Fig 9A ) . IIDA, KIJIMA, URATA, ET AL: EFFECT OF ANTI --GCS RIBOZYME ON THE MULTIDRUG RESISTANCE The results of electrophoretic mobility assay also showed that depletion of p53 protein increases the SP1 -DNA binding activity in HCT8DDP cells. Taken together, these results suggest that the mutant p53 in HCT8DDP cells can interact to inhibit its DNA -binding activity. The immunological estimation showed that levels of nuclear SP1 proteinins in HCT8DDP cells transfected with anti --GCS ribozyme were inversely associated with the SP1 -DNA binding activity ( Fig 9B ) , even though the mechanisms involved are not clear.
A relation between MDR1 and p53 has also been reported. Wild -type p53 induces the expression of MDR1, 59 and overexpression of MDR1 caused a down -regulation of p53, 60 suggesting that p53 mediates directly or indirectly the expression of MDR1. However, an inverse association between MDR1 and p53 was reported. 61 Such a difference in the effect of p53 on the expression of MDR1, as well as MRP1, is due to the status of p53. 52, 62 The finding, that the expression of MDR1 was suppressed in HCT8DDP cells transfected with anti --GCS ribozyme, may be due, in part, to interaction between SP1 and p53.
Another possible explanation for the regulation of the expression of ABC transporter genes by GSH is redox ( oxidation / reduction ) status. Quite recently, Wartenburg et al 63 reported that raising intracellular ROS by depletion of GSH using BSO resulted in a decline of MDR1 expression. The negative regulation of MDR1 by ROS may be also mediated by intracellular signaling pathways. Such ROSmediated mechanisms may be involved in the downregulation of MDR1 by transfection of anti --GCS ribozyme ( Fig 4 ) .
The expression of p53 is regulated by oxidative stress response elements, such as NF -B and AP -1. 64 It is interesting to know if GSH participates in the expression of ABC transporters through the regulation by p53. A role for GSH in the redox regulation of transcriptional factors and intracellular signal transduction pathways has been suggested. 65 In such cases, cysteine residues may be modified by GSH in the phosphorylation site of transcriptional factors or protein kinases. We have reported importance of GSH in regulation of the phosphorylation of IB -and NF -Bmediated expression of NF -B subunits by TNF -, 66 or the Fas -mediated apoptosis. 67 Similarly, it has been reported that increase in the intracellular GSH concentration by the transfection of -GCSh caused down -regulation of cytokine -induced activation of NF -B and AP -1. 23 Quite recently, Klatt et al 68 have reported that the DNA binding activity of c-Jun is down -regulated by GSH through its reversible S -glutathionylation and protein disulfide formation. The results in Figure 9 on the redox regulation by GSH in A2780 cells suggest that SP1 activity regulated by GSH is mediated by p53. The p53 gene expression may be regulated by GSH through oxidative stress response elements, although the molecular mechanisms are not clarified at the present time. The involvement of ROS in the relation between ABC transporter genes and p53 was not examined in the present study.
The role of the concentration of GSH in the expression of cMOAT is not fully understood. Transfection of cMOAT antisense cDNA to cancer cells caused an increase in GSH levels, 41 a result apposite to that observed in the present study. Further study is required.
In conclusion, transfection of cancer cells with the anti --GCSh hammerhead ribozyme caused a reduction of the GSH concentration and the expression of ABC transporters, leading to an increase in the sensitivity of the cancer cells to CDDP. Evidence that up -regulation of p53 observed in cancer cells transfected with anti --GCSh hammerhead ribozyme related to the suppression of DNA -binding activity of SP1 suggests, in turn, that GSH functions to suppress the expression of p53.
The results suggest that acquisition of resistance to CDDP in cancer cells accompanied by the induction of many factors such as GSH synthesis and ABC transporters, which leads to difficulty in anticancer chemotherapy, can be attenuated to same extent by using the anti --GCSh hammerhead ribozyme.
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